UroGen Pharma Ltd. (URGN)
NASDAQ: URGN · Real-Time Price · USD
43.25
-0.70 (-1.59%)
Sep 18, 2026, 4:00 PM EDT - Market closed
UroGen Pharma Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Operating Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -97.64 | -153.49 | -126.87 | -102.24 | -109.78 | -110.82 |
Depreciation & Amortization | 2.64 | 2.41 | 1.19 | 1.71 | 1.82 | 1.77 |
Other Amortization | - | - | - | - | 1.75 | - |
Asset Writedown & Restructuring Costs | - | 3.13 | - | - | - | - |
Loss (Gain) From Sale of Investments | -0.49 | -1.88 | -2.89 | -1.03 | -0.5 | 0.48 |
Stock-Based Compensation | 16.12 | 11.96 | 13.11 | 9.34 | 10.58 | 23.11 |
Other Operating Activities | 5.67 | 3.34 | 13.77 | 12.52 | 13.75 | 13.67 |
Change in Accounts Receivable | -69.11 | -12.78 | -4.86 | -2.74 | -0.99 | -4.67 |
Change in Inventory | -17.46 | -7.24 | -3.55 | -1.35 | -0.36 | -2.87 |
Change in Accounts Payable | 8.98 | 0.29 | 10.89 | 4.16 | 0.28 | 2 |
Change in Income Taxes | 0.11 | 0.11 | 0.6 | 0.18 | 0.18 | 0.13 |
Change in Other Net Operating Assets | -7.75 | -8.3 | 1.86 | 3.09 | -4.29 | -7.69 |
Operating Cash Flow | -158.92 | -162.44 | -96.77 | -76.38 | -87.56 | -84.89 |
Operating Cash Flow Growth | - | - | - | - | - | - |
Investing Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Capital Expenditures | -0.22 | -0.29 | -0.3 | -0.19 | -0.25 | -0.75 |
Investment in Securities | 40.32 | 61.85 | -20.32 | -0.76 | 1.31 | 4.82 |
Investing Cash Flow | 40.1 | 61.56 | -20.61 | -0.95 | 1.06 | 4.07 |
Financing Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Long-Term Debt Issued | - | - | 24.49 | - | 95.78 | - |
Long-Term Debt Repaid | - | -1.86 | - | - | - | - |
Net Debt Issued (Repaid) | 62.78 | -1.86 | 24.49 | - | 95.78 | - |
Issuance of Common Stock | 42.51 | 41.77 | 151.49 | 68.23 | 1.51 | 72.46 |
Other Financing Activities | -0 | - | 18.64 | 48.7 | -0.16 | -0.14 |
Financing Cash Flow | 105.29 | 39.92 | 194.62 | 116.93 | 97.13 | 72.32 |
Net Cash Flow
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Cash Flow | -13.53 | -60.97 | 77.24 | 39.6 | 10.64 | -8.5 |
Free Cash Flow
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -159.14 | -162.73 | -97.06 | -76.57 | -87.81 | -85.64 |
Free Cash Flow Growth | - | - | - | - | - | - |
Free Cash Flow Margin | -84.32% | -148.22% | -107.37% | -92.57% | -136.45% | -178.27% |
Free Cash Flow Per Share | -3.22 | -3.38 | -2.26 | -2.66 | -3.85 | -3.83 |
Levered Free Cash Flow | -106.98 | -99.42 | -46.83 | -35.16 | -42.79 | -44.14 |
Unlevered Free Cash Flow | -96.84 | -89.83 | -39.01 | -25.96 | -39.27 | -44.14 |